Trial record 9 of 92 for:    Open Studies | "Urinary Tract Infections"

Retrospective Analysis of Ialuril vs. Standard of Care in Recurrent Urinary Tract Infections (RAISC-RUTI)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by Study Group for Urogenital Diseases, Italy
Sponsor:
Information provided by (Responsible Party):
Massimo Lazzeri, Study Group for Urogenital Diseases, Italy
ClinicalTrials.gov Identifier:
NCT02016118
First received: October 7, 2013
Last updated: February 11, 2014
Last verified: February 2014
  Purpose

The purpose of this study is to assess the effectiveness and costs associated with the intravesical administration of combined hyaluronic acid (HA) and chondroitin sulphate (CS) compared to the current standard management of recurrent urinary tract infections in adult women diagnosed with recurrent urinary tract infections (RUTI).


Condition Intervention
Recurrent Urinary Tract Infections
Device: Ialuril

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: INTRAVESICAL ADMINISTRATION OF COMBINED HYALURONIC ACID (HA) AND CHONDROITIN SULPHATE (CS) vs. STANDARD OF CARE FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS (RUTIs)

Resource links provided by NLM:


Further study details as provided by Study Group for Urogenital Diseases, Italy:

Primary Outcome Measures:
  • Occurrence of Urinary tract infection recurrence [ Time Frame: within 12 months after treatment initiation ] [ Designated as safety issue: No ]
    At least one bacteriologically confirmed urinary tract infection experienced within 12 months after the treatment initiation.


Secondary Outcome Measures:
  • Occurrence of symptomatic urinary tract infection recurrence [ Time Frame: within 12 months after treatment initiation ] [ Designated as safety issue: No ]
    At least one symptoms based urinary tract infection experienced within 12 months after the treatment initiation.


Other Outcome Measures:
  • Mean direct overall costs [ Time Frame: within 12 months after treatment initiation ] [ Designated as safety issue: No ]
    Mean overall costs, expressed in euros, comprehensive of costs of each treatment options and other direct medical costs (i.e. visits, additional medical therapies required because of recurrences or adverse events, hospitalization) measured over 12 months after treatment initiation for each cohort of patients.

  • Number of days absent from work [ Time Frame: within 12 months after treatment initiation ] [ Designated as safety issue: No ]
    Number of days of absence from work due to the recurrent urinary tract infections within 12 months since the start of the treatment.

  • Time-to-recurrence [ Time Frame: 12 months after treatment initiation ] [ Designated as safety issue: No ]
    Time from the start of the treatment until the first occurrence of an objective or symptoms based urinary tract infection


Estimated Enrollment: 500
Study Start Date: January 2014
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Ialuril
Intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% once per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.
Device: Ialuril
The treatment is an intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% once per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.
Standard of care
Antimicrobial prophylaxis (continuous or postcoital), as described in the Guidelines on Urological Infections of the European Association of Urology or Immunoactive prophylaxis or Prophylaxis with probiotics or Prophylaxis with cranberry, or combination of these.

Detailed Description:

RUTI is defined as at least three episodes of uncomplicated urinary tract infections accompanied by clinical symptoms and documented by urine culture with the isolation of >103 colony forming units (CFU)/ml of an identified pathogen in the last year (M. Grabe, T.E. Bjerklund-Johansen, H. Botto, B. Wullt, M. Çek, K.G. Naber, R.S. Pickard, P. Tenke, F. Wagenlehner. Guidelines on Urological Infections. European Association of Urology 2012).

In order to do so, we will perform a retrospective analysis on prospectively collected patient data in nine European centres.

The treatment schedule for the intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% is one instillation per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.

The current standard management of RUTI in Europe is represented by the antimicrobial prophylaxis (continuous or postcoital), as described in the Guidelines on Urological Infections of the European Association of Urology or Immunoactive prophylaxis or Prophylaxis with probiotics or Prophylaxis with cranberry, or combination of these.

We will collect patient characteristics as age, BMI, sexual activity, employment status, severity of the disease, comorbidities.

Our primary clinical outcome will be the occurrence of objective (bacteriologically confirmed) recurrence within 12 months after the start of the treatment. Other outcomes will be the occurrence of clinical or symptoms based recurrence; the time to objective or symptoms based recurrence, evaluated from the start of the treatment until the first occurrence of an objective or symptoms based urinary tract infection, and the overall number of objective or symptoms based urinary tract infections experienced within 12 months after treatment initiation for RUTI.

Information about health related quality of life at baseline and 12 months will be recorded if available.

In terms of resource utilization, we will record the number of medical visits, number and types of laboratory, imaging and instrumental exams, hospitalization, consumption of pharmaceuticals or instrumental therapies (other than intervention and comparator) used within 12 months since treatment initiation. Number of days absent from work due to RUTI will be recorded when available. Costs will be attributed according to the perspective of the National Healthcare System searching for relevant data sources in each country.

Standard descriptive statistics, such as mean, median, range, and proportions, will be used to summarize patient characteristics and other collected variables. The Chi-Square test will be used to compare differences in proportions and the Mann-Whitney U test to compare continuous variables, with or without logarithmic transformation. The Kaplan-Meier method will be used to estimate time to recurrence outcomes.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

The study will consider women with recurrent urinary tract infections who started their treatments at the Urology Departments at the enrolling centres.

Criteria

Inclusion Criteria:

  • Women aged 18-75 years old.
  • Women diagnosed with recurrent urinary tract infections, defined as at least three episodes of uncomplicated urinary tract infections accompanied by clinical symptoms and documented by urine culture with the isolation of >103 CFU/ml of an identified pathogen in the last year. Uncomplicated or 'simple' UTI is defined as an infection in a person with normal urinary tract and function.

Exclusion criteria:

- Women with complicated urinary tract infections. Complicated urinary tract infection occurs in individuals with functional or structural abnormalities of the genitourinary tract.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02016118

Contacts
Contact: Massimo Lazzeri, PhD +393391072211 lazzeri.maximus@gmail.com

Locations
Italy
Ospedale S. Maria della Misericordia Recruiting
Perugia, Italy, 06156
Contact: Massimo Lazzeri, PhD    +393391072211    lazzeri.maximus@gmail.com   
Principal Investigator: Elisabetta Costantini, MD         
Sponsors and Collaborators
Study Group for Urogenital Diseases, Italy
Investigators
Principal Investigator: Massimo Lazzeri, PhD Università Vita-Salute San Raffaele
  More Information

Publications:
Responsible Party: Massimo Lazzeri, MD, PhD Consultant, Study Group for Urogenital Diseases, Italy
ClinicalTrials.gov Identifier: NCT02016118     History of Changes
Other Study ID Numbers: RAISC-RUTI
Study First Received: October 7, 2013
Last Updated: February 11, 2014
Health Authority: Italy: The Italian Medicines Agency

Keywords provided by Study Group for Urogenital Diseases, Italy:
RUTI

Additional relevant MeSH terms:
Urinary Tract Infections
Infection
Urologic Diseases
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 20, 2014